Results of Operations and Financial Condition. On August 5, 2026, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.

Director — Victor Dzau, M.D.: Dr. Victor Dzau was appointed to the Board of Directors and received standard non-employee director compensation.

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Results of Operations and Financial Condition. On May 6, 2026, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1.

Entry into a Material Definitive Agreement. On March 8, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to $2.0 billion of the Company’s common stock ( Common Stock ) before March 9, 2027. On March 9, 2026, the Company entered into two accelerated share repurchase agreements (the ASR Agreements ) with Citibank, N.A. ( Citi ) to repurcha…

Results of Operations and Financial Condition. On February 25, 2026, United Therapeutics Corporation issued a press release setting forth its earnings and business updates for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

Director — Kevin J. Tracey, M.D.: The filing discloses the appointment of a new independent director to the board, which is a routine governance action and not a departure of a senior executive.

Results of Operations and Financial Condition. On October 29, 2025, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

Entry into a Material Definitive Agreement. As previously disclosed on July 30, 2025, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to $1 billion of the Company’s common stock ( Common Stock ). On August 1, 2025, the Company entered into two accelerated share repurchase agreements (the ASR Agreements ) with Citibank, N.A. ( Citi ) to repurc…

Results of Operations and Financial Condition. On July 30, 2025, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The provided text is only the standard header for Item 5.02 and does not contain the specific details of the event required to classify the movement.

Results of Operations and Financial Condition. On April 30, 2025, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

below. The Credit Agreement also contains customary affirmative and negative covenants that, among other things, limit the ability of the Company and its subsidiaries to (a) in the case of subsidiaries that are not guarantors of the credit facility, incur indebtedness; (b) grant liens; (c) solely with respect to credit parties under the credit facility, enter into a merger, consolidation or amalgamation; (d) liquidate, wind up or dissolve; or (e) sell all or substantially all of the property,…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. On April 25, 2025, United Therapeutics Corporation (the “ Company ”) entered into a Credit Agreement (the “ Credit Agreement ”) with the lenders referred to therein and Wells Fargo Bank, National Association (“ Wells Fargo ”), as administrative agent and as a swingline lender. The Credit Agreement provides for an unsecured, revolving credit facility of up to $2.5 billion (which facility may, subject to obtaining commitments from existing or new lend…

Results of Operations and Financial Condition. On February 26, 2025, United Therapeutics Corporation issued a press release setting forth its earnings and business updates for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

Results of Operations and Financial Condition. On October 30, 2024, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

Results of Operations and Financial Condition. On July 31, 2024, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

The provided text is only the standard Item 5.02 header and does not contain the specific details of the management change required to classify the event.

Results of Operations and Financial Condition. On May 1, 2024, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. As previously reported, on March 31, 2022, United Therapeutics Corporation (the Company ) entered into a Credit Agreement (the Credit Agreement ) with certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association ( Wells Fargo ), as administrative agent and as a swingline lender. The Credit Agreement provides for (i) an unsecured revolving credit facility of up to $1.2 billion;…

Entry into a Material Definitive Agreement. On March 24, 2024, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to an aggregate of $1 billion of the Company’s common stock ( Common Stock ). On March 25, 2024, the Company entered into an accelerated share repurchase agreement (the ASR Agreement ) with Citibank, N.A. ( Citi ) to repurchase appro…